Intelligent Investment
Leiden Market
Global Life Sciences Atlas
April 11, 2025 5 Minute Read

Overview
- The Leiden Bio Science Park is the Netherlands’ main life sciences cluster due to the strong pharma and healthcare presence and close proximity to Amsterdam and Schiphol Airport.
- The park has significantly expanded over the last few years, with new developed buildings for Galapagos, Bristol Meyers Squibb, J&J, Batavia Biosciences and IFF, among others. The majority of the buildings are built-to-suit developments and therefore do not add to the park’s vacancy.
- Leiden Bio Science Park has limited vacancy of high-quality office and laboratory space. The lack of availability has led to lower absorption in 2023 and 2024, also driven by the decrease in venture capital investment. New buildings are scheduled to deliver in 2025 and 2026, which is expected to lead to more occupier movement and availability of high quality space. The lack of availability and upward yield movement has led to a significant increase in prime rents.
- Venture capital investments surged in 2021, post-COVID-19. Subsequent funding momentum trailed off into 2023, but rebounded in 2024.
Submarkets
Life Sciences Venture Capital Investment Trends
Figure 1: Life Sciences Venture Capital Funding
Life Sciences Market Stats
Figure 2: Inventory Lab/R&D
Figure 3: Supply Lab/R&D
Figure 4: Life Sciences Development Pipeline (Under Construction)
- Astellas
- Batavia Biosciences
- Bristol Meyers Squibb
- Eurofins
- Galapagos
- HAL Allergy
- IFF
- J&J
- LeydenLabs
- Pharming
- ProQR
- Thermofisher Scientific
- TNO
- Alrijne Hospital
- Biotech Training Facility
- Centre for Human Drug Research
- Hogeschool Leiden
- Leiden University
- Leiden University Medical Center
- Naturalis Biodiversity Center